Market Cap 162.91B
Revenue (ttm) 23.88B
Net Income (ttm) 3.90B
EPS (ttm) N/A
PE Ratio 29.87
Forward PE 29.87
Profit Margin 16.33%
Debt to Equity Ratio 0.33
Volume 1,270,231
Avg Vol 3,666,742
Day's Range N/A - N/A
Shares Out 706.35M
Stochastic %K 88%
Beta 0.89
Analysts Strong Sell
Price Target $257.05

Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 202 828 0850
Fax: 202 828 0860
Address:
2200 Pennsylvania Avenue N.W., Suite 800W, Washington, United States
EliteStockTrader
EliteStockTrader Dec. 31 at 6:32 PM
$DHR Current Price & Change: $230.16 (-0.22%) Trend Indicator: Bullish RSI Level: 50.1 Volume Activity: -87.4% vs avg Volatility: 1.23% Price Target: $230.50 Confidence: 87% I do not provide personalized financial advice or sell premium subscriptions. Any communication requesting payment for services is unauthorized. My only official outlet is https://stocksecret.news Always conduct your own due diligence.
0 · Reply
JustinTeel993
JustinTeel993 Dec. 31 at 5:20 PM
$BA $DHR $KLAC $PDD $TD Well reasoned
0 · Reply
OptionRunners
OptionRunners Dec. 30 at 8:30 PM
$DHR buyer of the January 16th 2026 $235 calls 1,000 times for $2.89
0 · Reply
TechTraderGrok
TechTraderGrok Dec. 29 at 11:14 PM
Bought $DHR at $230.68. From Grok: "Hold LONG—SunriseTrader holds "let it rides" post-ex-div, ChartMill bullish setup, analysts $243-270 PTs amid year-end strength." https://www.techtrader.ai/grokwall/?post=15940&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
OnlyFibs
OnlyFibs Dec. 28 at 2:48 AM
$DHR prints a series of Higher Lows into the $232 supply wall. The post-COVID inventory clearance is finally done, and the 0.56 put/call ratio confirms that no one wants to be short this lifecycle. The Setup: Textbook weekly trendline reclaim. We are wedged at the apex, waiting for that volume "push" through $233. Bull Level: A high-volume move through $233.96 clears the air for a fast gap-fill into the $258 yearly highs. Bear Risk: The absolute Line in the Sand is $204.32. Break that and the recovery resets. Catalyst: Jan 28th earnings are the next massive trigger for the new 6% core revenue expansion. 🚢📉 #hovdid
0 · Reply
TechTraderGrok
TechTraderGrok Dec. 26 at 9:12 PM
Sold $DHR at $230.46 (+6.7%). From Grok: "Exit long DHR near resistance at 235 after strong run-up from 215.79 entry, locking in gains amid overbought signals and no fresh catalysts, with next earnings around late January 2026." https://www.techtrader.ai/grokwall/?post=15932&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Neahrain8
Neahrain8 Dec. 24 at 4:55 PM
$NEE $ANET $VSNTV $BA $DHR I know it.
0 · Reply
StreamSniper
StreamSniper Dec. 24 at 3:49 PM
$DHR Strategic optionality narrows unless resilience of demand as cyclical tailwinds fade, with outcomes shaped by timing and discipline. Operational proof points remain decisive.
0 · Reply
HuntingBillions
HuntingBillions Dec. 24 at 2:16 AM
$DHR any new acquisitioons?
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 3:26 PM
Can $DHR keep growing on biotech strength — or is this peak momentum? 🔬 Biotechnology core revenues rose 6.5% in Q3 2025 on strong bioprocessing demand, and approximately 5% growth is expected in Q4, keeping this segment firmly in the driver’s seat. Find out if biotech can keep powering DHR’s growth 👉 https://www.zacks.com/stock/news/2806231/will-strength-in-biotechnology-unit-continue-to-drive-danahers-growth?cid=sm-stocktwits-2-2806231-teaser-25426&ADID=SYND_STOCKTWITS_TWEET_2_2806231_TEASER_25426
0 · Reply
Latest News on DHR
The Value Traps Of The REIT Sector

Dec 27, 2025, 8:50 AM EST - 4 days ago

The Value Traps Of The REIT Sector

ABNB BXP HST ILPT RMR SLG SVC


Danaher Schedules Fourth Quarter 2025 Earnings Conference Call

Dec 17, 2025, 7:30 AM EST - 14 days ago

Danaher Schedules Fourth Quarter 2025 Earnings Conference Call


Danaher Announces Quarterly Dividend

Dec 9, 2025, 4:15 PM EST - 22 days ago

Danaher Announces Quarterly Dividend


3 More Good Stocks to Invest In After Earnings

Nov 18, 2025, 4:29 PM EST - 6 weeks ago

3 More Good Stocks to Invest In After Earnings

FTNT LPLA


The Big 3: TMO, DHR, VLO

Nov 13, 2025, 12:50 PM EST - 6 weeks ago

The Big 3: TMO, DHR, VLO

TMO VLO


Danaher to Present at Jefferies Global Healthcare Conference

Nov 11, 2025, 4:15 PM EST - 7 weeks ago

Danaher to Present at Jefferies Global Healthcare Conference


Danaher: Regaining Growth Momentum

Oct 22, 2025, 10:49 AM EDT - 2 months ago

Danaher: Regaining Growth Momentum


Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript

Oct 21, 2025, 11:14 AM EDT - 2 months ago

Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript


Danaher Sales and Profit Rise on Bioprocessing Momentum

Oct 21, 2025, 6:23 AM EDT - 2 months ago

Danaher Sales and Profit Rise on Bioprocessing Momentum


Danaher Reports Third Quarter 2025 Results

Oct 21, 2025, 6:00 AM EDT - 2 months ago

Danaher Reports Third Quarter 2025 Results


Danaher Stock: Monopoly Margins, Discounted Price

Oct 15, 2025, 10:25 AM EDT - 2 months ago

Danaher Stock: Monopoly Margins, Discounted Price


4 Stocks That Aren't Too Hot to Buy Right Now

Oct 6, 2025, 2:45 PM EDT - 3 months ago

4 Stocks That Aren't Too Hot to Buy Right Now

EVRG KNTK PWR XLU


Danaher: Balanced Portfolio With Upside Potential In 2026

Oct 1, 2025, 6:33 AM EDT - 3 months ago

Danaher: Balanced Portfolio With Upside Potential In 2026


Danaher Schedules Third Quarter 2025 Earnings Conference Call

Sep 23, 2025, 4:15 PM EDT - 3 months ago

Danaher Schedules Third Quarter 2025 Earnings Conference Call


Analysts' Top S&P 500 Stocks to Buy Now

Sep 11, 2025, 2:26 PM EDT - 3 months ago

Analysts' Top S&P 500 Stocks to Buy Now

HWM SPGI


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 4 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX GRAL ILMN IONS MRNA RGEN


Danaher Stock Closes Near Day's High After Key Trading Signal

Aug 4, 2025, 7:13 AM EDT - 5 months ago

Danaher Stock Closes Near Day's High After Key Trading Signal


Danaher Appoints Jonathan Leiken as General Counsel

Jul 31, 2025, 4:15 PM EDT - 5 months ago

Danaher Appoints Jonathan Leiken as General Counsel


Danaher Q2 2025 Update

Jul 24, 2025, 3:30 PM EDT - 5 months ago

Danaher Q2 2025 Update


Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 1:18 PM EDT - 5 months ago

Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript


Cramer's Stop Trading: Danaher

Jul 22, 2025, 10:33 AM EDT - 5 months ago

Cramer's Stop Trading: Danaher


Danaher Announces Transition Plan for Chief Financial Officer

Jul 22, 2025, 6:02 AM EDT - 5 months ago

Danaher Announces Transition Plan for Chief Financial Officer


Danaher Reports Second Quarter 2025 Results

Jul 22, 2025, 6:00 AM EDT - 5 months ago

Danaher Reports Second Quarter 2025 Results


Danaher: High Capex And Low Debt Despite Trump Legislation

Jun 19, 2025, 12:33 PM EDT - 6 months ago

Danaher: High Capex And Low Debt Despite Trump Legislation


Danaher Schedules Second Quarter 2025 Earnings Conference Call

Jun 17, 2025, 4:30 PM EDT - 7 months ago

Danaher Schedules Second Quarter 2025 Earnings Conference Call


EliteStockTrader
EliteStockTrader Dec. 31 at 6:32 PM
$DHR Current Price & Change: $230.16 (-0.22%) Trend Indicator: Bullish RSI Level: 50.1 Volume Activity: -87.4% vs avg Volatility: 1.23% Price Target: $230.50 Confidence: 87% I do not provide personalized financial advice or sell premium subscriptions. Any communication requesting payment for services is unauthorized. My only official outlet is https://stocksecret.news Always conduct your own due diligence.
0 · Reply
JustinTeel993
JustinTeel993 Dec. 31 at 5:20 PM
$BA $DHR $KLAC $PDD $TD Well reasoned
0 · Reply
OptionRunners
OptionRunners Dec. 30 at 8:30 PM
$DHR buyer of the January 16th 2026 $235 calls 1,000 times for $2.89
0 · Reply
TechTraderGrok
TechTraderGrok Dec. 29 at 11:14 PM
Bought $DHR at $230.68. From Grok: "Hold LONG—SunriseTrader holds "let it rides" post-ex-div, ChartMill bullish setup, analysts $243-270 PTs amid year-end strength." https://www.techtrader.ai/grokwall/?post=15940&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
OnlyFibs
OnlyFibs Dec. 28 at 2:48 AM
$DHR prints a series of Higher Lows into the $232 supply wall. The post-COVID inventory clearance is finally done, and the 0.56 put/call ratio confirms that no one wants to be short this lifecycle. The Setup: Textbook weekly trendline reclaim. We are wedged at the apex, waiting for that volume "push" through $233. Bull Level: A high-volume move through $233.96 clears the air for a fast gap-fill into the $258 yearly highs. Bear Risk: The absolute Line in the Sand is $204.32. Break that and the recovery resets. Catalyst: Jan 28th earnings are the next massive trigger for the new 6% core revenue expansion. 🚢📉 #hovdid
0 · Reply
TechTraderGrok
TechTraderGrok Dec. 26 at 9:12 PM
Sold $DHR at $230.46 (+6.7%). From Grok: "Exit long DHR near resistance at 235 after strong run-up from 215.79 entry, locking in gains amid overbought signals and no fresh catalysts, with next earnings around late January 2026." https://www.techtrader.ai/grokwall/?post=15932&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Neahrain8
Neahrain8 Dec. 24 at 4:55 PM
$NEE $ANET $VSNTV $BA $DHR I know it.
0 · Reply
StreamSniper
StreamSniper Dec. 24 at 3:49 PM
$DHR Strategic optionality narrows unless resilience of demand as cyclical tailwinds fade, with outcomes shaped by timing and discipline. Operational proof points remain decisive.
0 · Reply
HuntingBillions
HuntingBillions Dec. 24 at 2:16 AM
$DHR any new acquisitioons?
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 3:26 PM
Can $DHR keep growing on biotech strength — or is this peak momentum? 🔬 Biotechnology core revenues rose 6.5% in Q3 2025 on strong bioprocessing demand, and approximately 5% growth is expected in Q4, keeping this segment firmly in the driver’s seat. Find out if biotech can keep powering DHR’s growth 👉 https://www.zacks.com/stock/news/2806231/will-strength-in-biotechnology-unit-continue-to-drive-danahers-growth?cid=sm-stocktwits-2-2806231-teaser-25426&ADID=SYND_STOCKTWITS_TWEET_2_2806231_TEASER_25426
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Dec. 18 at 1:33 PM
Biotech revolution is here, everyone eyes CRISPR stars — but real money in tools. Gold rush: picks and shovels. Biotech "shovels": $ILMN: Sequencing monopoly $TMO: Lab equipment giant $PACB: Long-read leader $DHR: Life science tools $BECT: Diagnostic king
0 · Reply
Arunas1
Arunas1 Dec. 17 at 6:50 PM
$DHR fell out of the channel probably $180 - $199 next. Sorry
0 · Reply
stockrandd
stockrandd Dec. 16 at 10:14 PM
$MRNA $VRTX $DHR $TNXP Have you heard about $BHST Are you Bullish? https://www.youtube.com/watch?v=VCRFmrw7nhQ
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:22 PM
Wells Fargo updates rating for Danaher ( $DHR ) to Equal-Weight, target set at 230 → 240.
0 · Reply
parcha
parcha Dec. 15 at 3:57 PM
$DHR Wells Fargo raised its price target on Club name Danaher to $240 from $230 and kept its hold rating. The life sciences company is turning the corner. It has to do with the next cycle, which has finally come because of stabilization in health-care spending. Danaher was one of the seven out-of-favor stocks to buy that I identified in Friday’s Monthly Meeting for Club members. https://www.cnbc.com/2025/12/15/jim-cramers-top-10-things-to-watch-in-the-stock-market-monday.html
0 · Reply
hoganbear
hoganbear Dec. 10 at 7:39 PM
$DHR OH FUCK YES!!!
0 · Reply
ripster47
ripster47 Dec. 10 at 11:58 AM
How To Find & Trade A+ #Earnings Setups $SBUX $LOGI $DHR @ripster47 | @tenet_research | @TenetCharts https://x.com/i/status/1998573506280534066
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Dec. 9 at 2:13 PM
$DHR Danny Hur ALWAYS disappoints
1 · Reply
hoganbear
hoganbear Dec. 9 at 2:12 PM
$DHR Danny Hurr is an absolute fucking tank $SPY
0 · Reply
erevnon
erevnon Dec. 9 at 12:50 PM
Goldman Sachs initiates coverage on Danaher $DHR at Buy rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 12:38 PM
Goldman Sachs has updated their rating for Danaher ( $DHR ) to Buy with a price target of 265.
0 · Reply
TipRanks
TipRanks Dec. 4 at 11:15 AM
Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks https://www.tipranks.com/news/article/morgan-stanley-ups-the-ante-on-these-2-life-science-tool-stocks $DHR $A
0 · Reply